Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New Methods for ALK An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In Situ Hybridization Assay

New Methods for ALK An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK... ORIGINAL ARTICLE New Methods for ALK Status Diagnosis in  Non–Small-Cell Lung Cancer An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In Situ Hybridization Assay Hiroaki Nitta, PhD, MBA,* Koji Tsuta, MD, PhD,† Akihiko Yoshida, MD, PhD,† Steffan N. Ho, MD, PhD,‡ Brian D. Kelly, PhD,* Lauren B. Murata, PhD,* Jerry Kosmeder, PhD,* Katie White, PhD,* Sandra Ehser, PhD,§ Penny Towne, MBA,* Crystal Schemp, MPH,* Abigail McElhinny, PhD,* Jim Ranger-Moore, PhD,* Chris Bieniarz, PhD,* Shalini Singh, MD,* Hitoshi Tsuda, MD, PhD,† and Thomas M. Grogan, MD* was similar in ALK detection sensitivity to the HQ-tyramide IHC sys- Introduction: The demonstration of anaplastic lymphoma kinase tem and was compatible with the brightfield in situ hybridization assay. (ALK) positivity in non–small-cell lung cancer (NSCLC) has been Conclusion: The new HQ-tyramide IHC reagent system allows more hindered by the technical complexity and interpretative challenges of sensitive assessment of ALK protein status in NSCLC cases. The new fluorescence in situ hybridization methods for detection of ALK gene ALK gene-protein assay allows the concurrent visualization of ALK rearrangement and by the inadequate sensitivity of existing immu- gene and ALK protein status in single cells, allowing more accurate nohistochemistry (IHC) methods for ALK protein detection. In this ALK status determination even http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

New Methods for ALK An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In Situ Hybridization Assay

Journal of Thoracic Oncology , Volume 8 (8) – Aug 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/new-methods-for-alk-an-improved-alk-immunohistochemical-assay-and-a-0ByjlgooBW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31829ebb4d
pmid
23817194
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE New Methods for ALK Status Diagnosis in  Non–Small-Cell Lung Cancer An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In Situ Hybridization Assay Hiroaki Nitta, PhD, MBA,* Koji Tsuta, MD, PhD,† Akihiko Yoshida, MD, PhD,† Steffan N. Ho, MD, PhD,‡ Brian D. Kelly, PhD,* Lauren B. Murata, PhD,* Jerry Kosmeder, PhD,* Katie White, PhD,* Sandra Ehser, PhD,§ Penny Towne, MBA,* Crystal Schemp, MPH,* Abigail McElhinny, PhD,* Jim Ranger-Moore, PhD,* Chris Bieniarz, PhD,* Shalini Singh, MD,* Hitoshi Tsuda, MD, PhD,† and Thomas M. Grogan, MD* was similar in ALK detection sensitivity to the HQ-tyramide IHC sys- Introduction: The demonstration of anaplastic lymphoma kinase tem and was compatible with the brightfield in situ hybridization assay. (ALK) positivity in non–small-cell lung cancer (NSCLC) has been Conclusion: The new HQ-tyramide IHC reagent system allows more hindered by the technical complexity and interpretative challenges of sensitive assessment of ALK protein status in NSCLC cases. The new fluorescence in situ hybridization methods for detection of ALK gene ALK gene-protein assay allows the concurrent visualization of ALK rearrangement and by the inadequate sensitivity of existing immu- gene and ALK protein status in single cells, allowing more accurate nohistochemistry (IHC) methods for ALK protein detection. In this ALK status determination even

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Aug 1, 2013

References